[Prostaglandin E1: effect on blood gases in infants with cyanotic congenital heart disease (author's transl)].
15 infants with cyanotic congenital heart disease (pulmonary atresia, Ebstein-Syndrom) were treated with Prostaglandin E1. During treatment there was a significant rise of PO2 and SO2 in the arterial, capillary and central venous blood. There was a minor rise of pH and HCO3; the arterial pCO2 fell slightly. We used PGE1-therapy as pretreatment before the heart operation, so that the critical babies go to the operation well oxygenated and in a better state. The side effects we observed (tachypnoe, tachycardia, hyperpyrexia, augmented urine output, erythemas, apnoic spells) seemed less important than the great advantage of a better oxygenation of these hypoxic babies.
D001639:Bicarbonates / Q000097:blood; D001769:Blood; D001784:Blood Gas Analysis; D002245:Carbon Dioxide / Q000097:blood; D005260:Female; D006330:Heart Defects, Congenital / Q000601:surgery; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010100:Oxygen / Q000097:blood; D010313:Partial Pressure; D011300:Preoperative Care; D011458:Prostaglandins E / Q000009:adverse effects / Q000494:pharmacology*; D011664:Pulmonary Valve / Q000002:abnormalities
D001639:Bicarbonates; D011458:Prostaglandins E; D002245:Carbon Dioxide; D010100:Oxygen
Prostaglandin E1: Wirkung auf die Blutgase bei zyanotischen Neugeborenen.